Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4423-4427

  Mielke, Stephan ^a,e   Sparreboom, Alex ^b,c   Behringer, Dirk ^a   Mross, Klaus ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Paclitaxel; Solid tumors

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INFUSION; DRUG RESPONSE; ESOPHAGUS CANCER; FEMALE; HEAD CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MALE; NECK CANCER; NEUROTOXICITY; OVARY CANCER; PENIS CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXICITY; URETER CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 28444461012     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
2. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P and Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158, 1998.
3. Perez EA, Vogel CL, Irwin DH, Kirshner JJ and Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001.
4. Wist EA, Sommer HH, Ostenstad B, Risberg T and Fjaestad K: Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43: 11-14, 2004.
5. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
6. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G and Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995.
7. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J and Sparreboom A: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19: 4065-4073, 2001.
8. Huizing MT, Keung AC, Rosing H, van dK, V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM and Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135, 1993.
9. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y and Saijo N: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606, 1995.
10. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J and Sparreboom A: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20: 574-581, 2002.
11. Mross K, Hollander N, Hauns B, Schumacher M and Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 45: 463-470, 2000.
12. Sparreboom A, van TO, Nooijen WJ and Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115, 1996.
13. Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermerken JB, Postmus PE, van ZN, Koolen MG, ten Bokkel Huinink WW, van d, V, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH and Beijnen JH: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15: 317-329, 1997.
14. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D and Mross K: Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11: 4843-4850, 2005.
15. Mielke S, Mross K, Gerds TA, Schmidt A, Wasch R, Berger DP, Lange W and Behringer D: Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14: 785-792, 2003.
16. Mross K, Haring B, Hollander N, Mielke S, Behringer D, Massing U and Unger C: Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie 25: 503-508, 2002.
17. Mielke S, Mross K, Gerds T A, Schmidt A, Lange W and Behringer D: A multicenter, randomized phase III study on neurotoxicity, safety and efficacy of weekly Paclitaxel infused over 1-h vs. 3-h in patients with advanced solid tumors. [Abstract] Eur J Cancer Suppl 1: 164, 2003.